ACOG advises against GLP-1 receptor agonists in pregnancy and recommends considering discontinuation 1 to 2 months before conception.
|Articles|December 6, 2011
Poll: What Was Your Favorite 2011 DailyDx?
Author(s)OBGYN.net Staff
The DailyDx is one of the hottest sections. Tell us what your favorite DailyDx in 2011 was. Here are our picks, vote on them or add your favorite pick in a comment.
Advertisement
If your favorite is not listed, check the
Advertisement
Related to this article
Joint guidance from the AHA, AAP, ACOG, and SMFM organizes cardiovascular prevention for girls and women around 4 female life stages.
Experts address COVID-19 vaccine myths, safety evidence, and how to frame the benefits of vaccination in pregnancy.
Experts look ahead to new maternal vaccines and how to counsel patients on receiving several in one pregnancy.
Experts discuss common patient concerns about vaccination in pregnancy and strategies to improve uptake.
Experts discuss how obstetric and pediatric clinicians can coordinate to protect newborns.
Experts review ACOG's 2026-27 guidance and the RSV window extension for pregnant and postpartum patients.
On September 9, 2026, certolizumab pegol received FDA Breakthrough Therapy Designation for APS pregnancy; Jane E. Salmon, MD, reviews the IMPACT trial results behind it.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
ACOG advises against GLP-1 receptor agonists during pregnancy
2
Safety Monitoring and Dosing for NK3 Antagonists in Menopause VMS
3
Matthew Nudy, MD, on estrogen and the cardiovascular system
4
Susan Reed, MD, on the future of menopause research and funding
5